Dorthe Skovgaard News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share Half were given the jab and half a placebo. They completed surveys on their eating habits and appetite at the start of the trial and again after 20 weeks. They had a set breakfast, followed by an unlimited lunch five hours later. Patients on the drug ate 1,736 calories at lunch, which was 940 fewer than those on the placebo. Those given the jab lost 9.9 per cent of their body weight on average, compared with 0.4 per cent in those on the dummy drug.  Patients on the medication reported a smaller appetite and better hunger control during the study.  The jab is available at a dose of 1mg...

 E-Mail New research presented at this year's European Congress on Obesity (held online, 10-13 May) shows that the obesity drug semaglutide reduces appetite, food cravings and energy intake in people given a meal where they could eat as much as they liked. The study is by Dr Dorthe Skovgaard, Novo Nordisk A/S (the manufacturer of the drug), Søborg, Denmark, and colleagues. Semaglutide, in the glucagon-like peptide-1 (GLP-1) analogue drug class, is currently available at the dose of 1.0 mg injected once weekly for the treatment of type 2 diabetes and is under development for chronic weight m...